Adam Kroetsch at Policy and Practice: We need clinical trial abundance. When trials are slow and costly, it doesn’t just hurt the pharmaceutical industry that pays for the trials – it limits how many treatments reach patients and how quickly they arrive. Less expensive, more abundant trials would le.
Less expensive, more abundant trials would le.